The Peer-Reviewed Forum for Real-World Evidence in Benefit Design ™ July 2013
Volume 6, Number 5
For Payers, Purchasers, Policymakers, and Other Healthcare Stakeholders
Hematology/Oncology Theme Issue EDITORIAL
Increasing Importance of Oncology Drug Management for Payers James T. Kenney, Jr, RPh, MBA
The Changing Face of Cancer Care: Evolution to a Collaborative Model Michael Kolodziej, MD, FACP PERSPECTIVES ™
Defining Value in Cancer Care: AVBCC 2013 Steering Committee Report Linda Bosserman, MD, FACP; Douglas Burgoyne, PharmD; Craig K. Deligdish, MD; John E. Hennessy, CMPE; James T. Kenney, Jr, RPh, MBA; Kevin B. Knopf, MD, MPH; James Lang, PharmD; Grant D. Lawless, MD, RPh, FACP; Douglas M. Long; Jennifer Malin, MD, PhD; Thomas A. Marsland, MD; Patrick McKercher, RPh, PhD; Leonard Natelson; Gary M. Owens, MD; Matthew C. Palmgren, PharmD; Lillie D. Shockney, RN, BS, MAS; Jayson Slotnik, JD, MPH; F. Randy Vogenberg, RPh, PhD; Burt Zweigenhaft, BS CLINICAL
Patient-Reported Outcomes Are Changing the Landscape in Oncology Care: Challenges and Opportunities for Payers Erin Zagadailov, PharmD, MS; Michael Fine, MD; Alan Shields, PhD Stakeholder Perspective by Matthew Mitchell, PharmD, MBA BUSINESS
Rapid Expansion of New Oncology Care Delivery Payment Models: Results from a Payer Survey Rhonda Greenapple, MSPH Stakeholder Perspective by Gary M. Owens, MD
Review of US Comparative Economic Evidence for Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line VEGF Inhibitor Therapy
6
EST. 2008
YEAR ANNIVERSARY
Michael K. Wong, MD, PhD; Xufang Wang, MD, MBA; Maruit J. Chulikavit, MPH; Zhimei Liu, PhD Stakeholder Perspective by Nicholas J. Vogelzang, MD
www.AHDBonline.com ©2013 Engage Healthcare Communications, LLC